Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | TCF4 | P15884 | 2/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565563 | 1.00 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2NAMPTPOLB | |
| SCHEMBL565841 | 0.91 | PTPN1 (0.48) | MEN1KMT2APOLBCYP19A1MGAT2 | |
| SCHEMBL565842 | 0.91 | PTPN1 (0.48) | MEN1KMT2APOLBCYP19A1MGAT2 | |
| SCHEMBL4904804 | 0.76 | HTR2B (0.39) | MEN1KMT2ASMN1; SMN2POLBPTPN1 | |
| SCHEMBL4904809 | 0.76 | HTR2B (0.39) | MEN1KMT2ASMN1; SMN2POLBPTPN1 | |
| SCHEMBL23686218 | 0.74 | PTPN1 (0.46) | MEN1KMT2APOLBCYP19A1PTPN1 | |
| SCHEMBL4904489 | 0.74 | TP53 (0.45) | MEN1KMT2APOLBPTPN11MAPT | |
| SCHEMBL4904487 | 0.74 | TP53 (0.45) | MEN1KMT2APOLBPTPN11MAPT | |
| SCHEMBL4897722 | 0.74 | POLB (0.47) | MEN1KMT2APOLBMGAT2PTPN1 | |
| SCHEMBL4897715 | 0.74 | POLB (0.47) | MEN1KMT2APOLBMGAT2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150352131-A1 | Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis | RHODE ISLAND HOSPITAL (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150352131-A1 | Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis | RHODE ISLAND HOSPITAL (US) | 2015-12-10 | — | — | US | disclosed |
| US-8623906-B2 | Carboxy isatin hydrazones and their esters as Shp2 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120034186-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352131-A1 | Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis | SOST, PTPN6, PTPN3 | MEN1 4285/4885KMT2A 3106/4885SMN1; SMN2 3715/4885 |
| US-20120034186-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | PTPN1, PTPN2, PTPN7 | MEN1 4051/4885KMT2A 1600/4885SMN1; SMN2 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.